Federal Register / Vol. 88, No. 189 / Monday, October 2, 2023 / Notices 67775 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.14, Intramural Research 

Training Award; 93.22, Clinical Research 

Loan Repayment Program for Individuals 

from Disadvantaged Backgrounds; 93.232, 

Loan Repayment Program for Research 

Generally; 93.39, Academic Research 

Enhancement Award; 93.936, NIH Acquired 

Immunodeficiency Syndrome Research Loan 

Repayment Program; 93.187, Undergraduate 

Scholarship Program for Individuals from 

Disadvantaged Backgrounds, National 

Institutes of Health, HHS) 

Dated: September 27, 2023. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–21686 Filed 9–29–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Research and Development 

of Vaccines and Monoclonal Antibodies for 

Pandemic Preparedness (ReVAMPP) Centers 

for Bunyavirales, Paramyxoviridae and 

Picornoviridae (U19 Clinical Trial Not 

Allowed). 

Date: November 7–9, 2023. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Rockville, MD 

20892 (Virtual Meeting). 

Contact Person: Frank S. De Silva, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, MSC 9823, Rockville, MD 

20892–9823, (240) 669–5023, fdesilva@

niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: September 26, 2023. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–21740 Filed 9–29–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Proposed Collection; 60-Day Comment 

Request; ABCD Study® Audience 

Feedback Teams (National Institute on 

Drug Abuse) 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: In compliance with the 

requirement of the Paperwork 

Reduction Act of 1995 to provide 

opportunity for public comment on 

proposed data collection projects, the 

National Institute on Drug Abuse 

(NIDA) will publish periodic summaries 

of proposed projects to be submitted to 

the Office of Management and Budget 

(OMB) for review and approval. 

DATES: Comments regarding this 

information collection are best assured 

of having their full effect if received 

within 60 days of the date of this 

publication. 

FOR FURTHER INFORMATION CONTACT: To 

obtain a copy of the data collection 

plans and instruments, submit 

comments in writing, or request more 

information on the proposed project, 

contact: Dr. Kimberly LeBlanc Scientific 

Program Manager, Division of 

Extramural Research, National Institute 

on Drug Abuse, C/O NIH Mail Center/ 

Dock 11, 3WFN Room 09C77 MSC 6021, 

Gaithersburg, MD 20877 (20892 for 

USPS), or call non-toll-free number 

(301) 827–4102, or Email your request, 

including your address, to: 

kimberly.leblanc@nih.gov. Formal 

requests for additional plans and 

instruments must be requested in 

writing. 

SUPPLEMENTARY INFORMATION: Section 

3506(c)(2)(A) of the Paperwork 

Reduction Act of 1995 requires: written 

comments and/or suggestions from the 

public and affected agencies are invited 

to address one or more of the following 

points: (1) Whether the proposed 

collection of information is necessary 

for the proper performance of the 

function of the agency, including 

whether the information will have 

practical utility; (2) The accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; (3) 

Ways to enhance the quality, utility, and 

clarity of the information to be 

collected; and (4) Ways to minimizes 

the burden of the collection of 

information on those who are to 

respond, including the use of 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms of 

information technology. 

Proposed Collection Title: Adolescent 

Brain & Cognitive Development (ABCD) 

StudySM—Audience Feedback Teams, 

0925 –NEW, exp., date XX/XX/XXXX, 

National Institute on Drug Abuse 

(NIDA), National Institutes of Health 

(NIH). 

Need and Use of Information 

Collection: The purpose of this 

information collection request is to 

solicit audience feedback to improve the 

data collection process for the 

Adolescent Brain Cognitive 

Development (ABCD) Study. Started in 

2015, the ABCD Study® follows a cohort 

of over 10,000 young people from preadolescence into adulthood to 

understand how growing brains are 

shaped by experiences and biology. To 

prepare for each year’s Study data 

collection, the National Institute of 

Health is collecting audience feedback 

on a selection of survey questions and 

research protocols. Parents/caregivers 

and teens who are the same age as the 

study cohort members but who are not 

Study participants will review proposed 

questions and give feedback on 

questions’ clarity and acceptability. 

Recommendations from these findings 

help the ABCD Study team improve 

their protocol for a more-successful data 

collection. 

Audience feedback activities will 

include a mix of asynchronous and 

scheduled, live data collection: webbased survey activities, virtual 

discussion boards, individual 

interviews, and discussions groups. 

Assembling a cohort of audience 

feedback participants who are familiar 

with the ABCD Study and participate in 

multiple data collection activities 

minimizes the burden required to 

familiarize new participants with the 

purpose of the Study and the 

expectations for audience feedback. 

OMB approval is requested for 3 

years. There are no costs to respondents 

other than their time. The total 

estimated annualized burden hours are 

172. 


lotter on DSK11XQN23PROD with NOTICES1
67776 Federal Register / Vol. 88, No. 189 / Monday, October 2, 2023 / Notices 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Number of 

respondents 

Number of 

responses per 

respondent 

Average 

time per 

response 

(in hours) 

Total annual 

burden hour 

Individuals (Teen Phone Screener) ................................................................. 72 1 5/60 6 

Individuals (Teen Assent or Consent) ............................................................. 36 1 10/60 6 

Individuals (Teen Web Survey) ....................................................................... 36 2 30/60 36 

Individuals (Teen Virtual Group Discussion or Online Bulletin Board) ........... 36 2 1 72 

Individuals (Parent/Caregiver Phone Screener) .............................................. 72 1 5/60 6 

Individuals (Parent/Caregiver Permission for Teen Participation) ................... 36 1 5/60 3 

Individuals (Parent/Caregiver Consent) ........................................................... 15 1 5/60 1 

Individuals (Parent/Caregiver Web Survey) .................................................... 15 2 30/60 15 

Individuals (Parent/Caregiver Virtual Interview) .............................................. 15 1 30/60 8 

Individuals (Parent/Caregiver Online Bulletin Board) ...................................... 15 1 1 15 

Individuals (Parent/Caregiver ‘‘At-Home’’ Materials Review) .......................... 15 1 15/60 4 

Total .......................................................................................................... ........................ 450 ........................ 172 

Lanette A. Palmquist, 

Project Clearance Liaison, National Institute 

on Drug Abuse, National Institutes of Health. 

[FR Doc. 2023–21698 Filed 9–29–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Healthcare Delivery 

and Methodologies Integrated Review Group, 

Community Influences on Health Behavior 

Study Section. 

Date: October 24–25, 2023. 

Time: 9:30 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Washington Plaza Hotel, 10 Thomas 

Circle, NW Washington, DC 20005. 

Contact Person: Annie Laurie McRee, 

DRPH, Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 100, 

Bethesda, MD 20892, (301) 827–7396, 

mcreeal@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, Special 

Topics: Neuroimaging Technologies. 

Date: October 25, 2023. 

Time: 9:30 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Mufeng Li, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (240) 507–9155, mufeng.li@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel, PAR Panel: 

Research on Current Topics in Alzheimer’s 

Disease and its Related Dementias. 

Date: October 26–27, 2023. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Mei Qin, MD, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5213, 

Bethesda, MD 20892, 301–875–2215, 

qinmei@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: September 26, 2023. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–21608 Filed 9–29–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Infectious Diseases 

and Immunology A Integrated Review Group; 

HIV Molecular Virology, Cell Biology, and 

Drug Development Study Section. 

Date: November 13–14, 2023. 

Time: 8:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Ritz-Carlton Hotel, 1700 Tysons 

Boulevard, McLean, VA 22102. 

Contact Person: Kenneth A. Roebuck, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5214, 

MSC 7852, Bethesda, MD 20892, (301) 435– 

1166, roebuckk@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Nucleic 

Acid Therapeutic Delivery (NATD). 

Date: November 14–15, 2023. 

Time: 9:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 


lotter on DSK11XQN23PROD with NOTICES1